ID

4181

Descripción

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Inclusion Criteria: - Patient must have been previously enrolled in Protocol 93-04-11 and randomized to the placebo arm; or the patient met all eligibility criteria for protocol 93-04-11 other than the expression of CD25 on CTCL tumor cells. - CTCL disease Stage Ia - III. - History of less than or equal to 3 previous therapies. Repeated use of the same agent is considered to be 1 therapy unless it is part of a different combination regimen. Only 1 prior combination cytotoxic chemotherapy regimen is permitted. Topical or systemic steroids are not considered a therapy. - Patient must have evaluable or measurable disease. Lymph node involvement no greater than LN2. No CTCL involvement of bone marrow. - No significant pulmonary or cardiac disease. No active CNS, kidney, or liver disease. No systemic infections. - ECOG performance status of 0 or 1. Exclusion Criteria: - The 93-04-14 study is no longer open to subjects previously enrolled in 93-04-10 or 92-04-01

Palabras clave

Versiones (1)

1. 10/11/13 10/11/13 - Martin Dugas

Subido en

10 de noviembre de 2013

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia